Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00924040 · OUTCOME

Correlation Between Number of Prior Cycles of BL22 With Immunogenicity on This Protocol

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia · Source last updated 2015-10-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
correlation coefficient
Interval / dispersion
Not reported
Time frame
Within 2 months of end of treatment ( measure antibodies before each cycle)

What was measured

Percent of patients neutralizing \>75% of 1000 ng/ml of BL22 in a biologic assay by end of treatment, with respect to the number of prior cycles of BL22 prior to entry on this protocol

Groups in this outcome

BL22 Immunotherapy

30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BL22 Immunotherapy1

Reported measurements

Source class 1
Values in correlation coefficient · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BL22 Immunotherapy0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Percent of patients neutralizing \>75% of 1000 ng/ml of BL22 in a biologic assay by end of treatment, with respect to the number of prior cycles of BL22 prior to entry on this protocol
groups
  1. description
    30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
    id
    OG000
    title
    BL22 Immunotherapy
param Type
NUMBER
reporting Status
POSTED
time Frame
Within 2 months of end of treatment ( measure antibodies before each cycle)
title
Correlation Between Number of Prior Cycles of BL22 With Immunogenicity on This Protocol
type
SECONDARY
unit Of Measure
correlation coefficient

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice